October 31, 2003

News Release: Genitope Corporation Announces Initial Public Offering

REDWOOD CITY, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Genitope Corporation (Nasdaq: GTOP) today announced the initial public offering of 3,700,000 shares of its common stock at $9.00 per share on the NASDAQ National Market under the trading symbol 'GTOP.'Genitope has granted the underwriters the right to purchase up
to an additional 555,000 shares of common stock to cover over allotments, if any. All of such shares are being offered by Genitope Corporation. WR Hambrecht + Co is acting as the lead underwriter of the offering. Punk, Ziegel & Company and Brean Murray & Co., Inc. are acting as co-managers. Shares are being offered only by prospectus. Copies of the final prospectus for the offering may be obtained by contacting WR Hambrecht + Co, LLC at P.O. Box 677, Berwyn, PA 19312-0677, or by telephone at 800-673-6476, or by faxing a request to 610-725-1167; or Punk, Ziegel & Company, L.P. at 520 Madison Avenue, 7th Floor, New York, NY 10022, or by telephone at 212-308-9494, or by faxing a request to 212-308-2203; or Brean Murray & Co., Inc. at 570 Lexington Avenue, 11th Floor, New York, NY 10022, or by telephone at 212-702-6500, or by faxing a request at 212-702-6548.

The offering is made only by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.



About Genitope Corporation

Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(TM) Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.



CONTACT: Fred Kurland, Chief Financial Officer of Genitope Corporation, +1-650-482-2000, or This email address is being protected from spambots. You need JavaScript enabled to view it.; or Krysta Walkowiak of Dorland Public Relations, +1-415-262-5211, or This email address is being protected from spambots. You need JavaScript enabled to view it., for Genitope Corporation.



CONTACT: Fred Kurland, Chief Financial Officer of Genitope Corporation,
+1-650-482-2000, or This email address is being protected from spambots. You need JavaScript enabled to view it.; or Krysta Walkowiak of Dorland Public
Relations, +1-415-262-5211, or This email address is being protected from spambots. You need JavaScript enabled to view it., for Genitope
Corporation.

SOURCE Genitope Corporation
Web Site: http://www.genitope.com

WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.